As of Aug. 8, EG.5 accounts for 17.3 percent of COVID-19 cases. Other leading variants include XXB.1.16 with 15.6 percent of infections, XBB.2.3 with 11.2 percent and XBB.1.5 with 10.3 percent.
Some experts have nicknamed EG.5 “Eris,” but the WHO has not officially named it.
The variant’s prevalence has risen globally since late May, according to the WHO, but there is no evidence linking EG.5 with higher transmission rates or infection severity. The upcoming tweaked boosters will target XBB.1.5 — which was the dominant variant when the FDA advised vaccine-makers in June to alter their formulas — but health experts predict the shots will be effective because XBB.1.5 is mostly similar in mutations.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
